Why Patients Are Making This Switch Right Now
Swap From Mounjaro to Wegovy: Complete UK Stock Availability
The decision to swap from Mounjaro to Wegovy has become significantly easier with consistent UK stock levels now available through EverydayMeds. Unlike the supply shortages that affected semaglutide availability throughout 2022-2023, our direct partnership with Novo Nordisk ensures reliable access to all five Wegovy doses. Patients no longer need to worry about treatment interruptions or rationing when making this transition, as we maintain comprehensive inventory levels across the entire dose escalation schedule.
When you swap from Mounjaro to Wegovy through our platform, you're accessing genuine UK-licensed medicine stored under strict temperature-controlled conditions. Our GPhC-registered pharmacy (#9012878) processes orders through standard 3-day or express 24-hour prescriber review, ensuring clinical continuity during your treatment transition. The streamlined ordering system eliminates the uncertainty that previously made switching between GLP-1 medications a complex process for UK patients.
Wegovy Pricing Structure for Treatment Transitions
Understanding the cost implications when you swap from Mounjaro to Wegovy requires examining our transparent pricing structure across all dose strengths. Starting doses begin at £79.99 for the 0.25mg pen, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. New customers applying discount code FIRST40 at checkout reach these final prices, while returning customers use code DOSE25 for equivalent savings.
Our Getting Started bundles provide convenient multi-dose packages for those planning their entire escalation schedule when making the swap from Mounjaro to Wegovy. The Intro Duo (0.25mg & 0.5mg) costs £169.99, covering your first 8 weeks of treatment, while the Progress Duo (0.5mg & 1mg) at £189.99 suits patients beginning at higher starting doses. These bundles ensure treatment continuity without multiple separate orders during the critical transition period.
Clinical Evidence Supporting the Swap From Mounjaro to Wegovy
The STEP clinical trial programme demonstrates semaglutide's efficacy profile for patients considering this medication transition. In the pivotal STEP 1 trial (Wilding et al., NEJM, 2021), patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. The STEP 5 extension data showed sustained 15.2% weight reduction maintained at 2 years, providing confidence for long-term treatment planning.
Recent SELECT cardiovascular outcomes data adds another dimension for patients who swap from Mounjaro to Wegovy, demonstrating a 20% reduction in major cardiovascular events (hazard ratio 0.80). This evidence base supports clinical decision-making beyond weight management alone, particularly for patients with existing cardiovascular risk factors who may benefit from semaglutide's proven cardioprotective effects alongside metabolic improvements.
Understanding Wegovy's Mechanism When Switching Treatments
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to support appetite regulation. Unlike Mounjaro's dual GIP and GLP-1 receptor targeting, Wegovy focuses specifically on GLP-1 pathways to reduce appetite and promote satiety after smaller meals. This targeted approach may suit patients who experienced specific side effects with tirzepatide's broader mechanism or those whose prescribers prefer single-receptor targeting. The once-weekly injection schedule remains consistent between treatments, maintaining dosing convenience during your transition. Many patients report that Wegovy's mechanism produces different subjective effects around food cravings and meal satisfaction compared to Mounjaro's dual-hormone approach.
Streamlined Ordering Process for Treatment Transitions
Switching from Mounjaro to Wegovy through EverydayMeds begins with our 3-minute online clinical assessment, designed to capture your treatment history and transition requirements efficiently. Our prescribers review your medical information within 3 working days (or 24 hours with express service), specifically considering the clinical rationale for changing between GLP-1 medications and ensuring appropriate dose selection. Once approved, your Wegovy prescription ships via next-day delivery using temperature-controlled packaging that maintains the 2-8°C storage requirements throughout transit. The entire process from assessment to delivery typically completes within 5 working days, minimising any gap between treatments during your medication transition.
Storage and Practical Advantages of Making This Switch
One significant practical benefit when you swap from Mounjaro to Wegovy involves storage flexibility, particularly for travel and lifestyle management. Wegovy maintains stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This extended temperature tolerance provides greater confidence for business trips, holidays, or daily routine flexibility without strict refrigeration requirements. The FlexTouch pen delivery system offers precise dose administration with clear visual confirmation, and the 16-week escalation schedule from 0.25mg to 2.4mg maintenance follows established protocols that most patients tolerate well. Both medications require similar injection techniques and weekly scheduling, making the practical transition straightforward for experienced users.
Why UK Patients Are Choosing This Treatment Swap Now
Current supply chain stability represents a crucial factor driving patient decisions to swap from Mounjaro to Wegovy in 2026. The historical availability challenges that affected semaglutide products have resolved, with consistent stock levels now maintained across all dose strengths through our Novo Nordisk partnership. Many prescribers are recommending this transition for patients who experienced specific tolerability issues with tirzepatide or those requiring the proven cardiovascular benefits demonstrated in the SELECT trial data.
The established clinical evidence base supporting long-term semaglutide use provides additional confidence for patients planning extended weight management treatment. With over 4 years of real-world safety data and comprehensive trial follow-up, Wegovy offers a well-characterized risk-benefit profile that supports informed treatment decisions. Our UK-based clinical team regularly assists patients through this transition process, ensuring continuity of care and appropriate monitoring throughout the medication change.
Complete Your Treatment Transition with Confidence
Ready to swap from Mounjaro to Wegovy with Stock Available availability and rapid UK delivery? Our comprehensive service includes clinical assessment, prescriber review, and temperature-controlled shipping to ensure seamless treatment continuity. New customers apply discount code FIRST40 at checkout, while returning patients use DOSE25 for immediate savings on all dose strengths. Visit our complete Wegovy collection at https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment today. Our GPhC-registered pharmacy (#9012878) maintains the highest standards for prescription-only medicine handling, ensuring your treatment transition meets full regulatory compliance and clinical safety requirements. The combination of proven efficacy, reliable supply, and expert support makes this the ideal time to complete your medication switch with confidence.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
